An association between BPDE-like DNA adduct levels and CYP1A1 and GSTM1 polymorphisma in pterygium

Molecular Vision

Volumn 16, Issue , 2010, Pages 623-629

  Tung, Jai Nien ^a,b   Wu, Heng Hsiung ^a   Chiang, Chun Chi ^a,c   Tsai, Yi Yu ^a,c   Chou, Ming Chih ^a   Lee, Huei ^a   Cheng, Ya Wen ^a,d  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZO[A]PYRENE 7,8 DIHYDRODIOL 9,10 OXIDE; CYTOCHROME P450 1A1; GLUTATHIONE TRANSFERASE M1; POLYCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DNA EXTRACTION; FEMALE; GENE LOCATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PTERYGIUM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TISSUE DISTRIBUTION;

7,8-DIHYDRO-7,8-DIHYDROXYBENZO(A)PYRENE 9,10-OXIDE; AGED; AGED, 80 AND OVER; CYTOCHROME P-450 CYP1A1; DNA ADDUCTS; EPITHELIAL CELLS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PTERYGIUM; RISK FACTORS; SEX CHARACTERISTICS;

EID: 77955619317     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Tan DT, Lim AS, Goh HS, Smith DR. Abnormal expression of the p53 tumor suppressor gene in the conjunctiva of patients with pterygium. Am J Ophthalmol 1997; 123:404-405. [PMID: 9063255]
2. Dushku N, Reid TW. P53 expression in altered limbal basal cells of pingula, pterygia, and limbal tumors. Curr Eye Res 1997; 16:1179-1192. [PMID: 9426949]
3. Onur C, Orhan D, Orhan M, Dizbay Sak S, Tulunay O, Irkeç M. Expression of p53 protein in pterygia. Eur J Ophthalmol 1998; 8:157-161. [PMID: 9793769]
4. Chowers I, Pe'er J, Zamir E, Livni N, Ilsar M, Frucht-Pery J. Proliferative activity and p53 expression in primary and recurrent pterygia. Ophthalmology 2001; 108:985-988. [PMID: 11320032]
5. Weinstein O, Rosenthal G, Zirkin H, Monos T, Lifshitz T, Argov S. Overexpression of p53 tumor suppressor gene in pterygia. Eye 2002; 16:619-621. [PMID: 12194078]
6. Tan DT, Tang WY, Liu YP, Goh HS, Smith DR. Apoptosis and apoptosis related gene expression in normal conjunctiva and pterygium. Br J Ophthalmol 2000; 84:212-216. [PMID: 10655200]
7. Dushku N, Hatcher SLS, Albert DM. P53 expression and relation to human papillomavirus infection in pinguecula, pterygia, and limbal tumors. Arch Ophthalmol 1999; 117:1593-1599. [PMID: 10604662]
8. Tsai YY, Cheng YW, Lee H, Tsai FJ, Tseng SH, Chang KC. P53 gene mutation spectrum and the relationship between gene mutation and protein expression in pterygium. Mol Vis 2005; 11:50-55. [PMID: 15682042]
9. Lee H, Su SY, Liu KS, Chou MC. Correlation between meteorological conditions and mutagenicity of airborne particulate samples in a tropical monsoon climate area from Kaohsiung city, Taiwan. Environ Mol Mutagen 1994; 23:200-207. [PMID: 8162895]
10. Kuo CY, Cheng YW, Chen CY, Lee H. Correlation between the amounts of polycyclic aromatic hydrocarbons and mutagenicity of airborne particulate samples from Taichung city, Taiwan. Environ Res 1998; 78:43-49. [PMID: 9630444]
11. Hussain SP, Amstad P, Raja K, Sawyer M, Hofseth L, Shields PG, Hewer A, Phillips DH, Ryberg D, Haugen A, Harris CC. Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations innontumorous human lung. Cancer Res 2001; 61:6350-6355. [PMID: 11522624]
12. Shimada T, Yun CH, Yamasaki H, Gautier C, Beaune PH, Guengerich P. Characterization of human lung microsomal cytochrome P450 1A1 and its role in the oxidation of chemical carcinogens. Mol Pharmacol 1992; 41:856-864. [PMID: 1588920]
13. London SJ, Daly AK, Leathart JBS, Navidi WC, Idle JR. Lung cancer risk in relation to the CYP2C9*1/CYP2CP*2 genetic polymorphism among Africa-Americans and Caucasians in Los Angeles County, California. Pharmacogenetics 1996; 6:527-33. [PMID: 9014202]
14. Bartsch H, Nair U, Risch A, Rojas M, Wilkman H, Alexandrov K. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers.Cancer Epidemiol Biomarkers Prev 2000; 9:3-28. [PMID: 10667460]
15. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett 1990; 263:131-133. [PMID: 1691986]
16. Hayashi S, Watanabe J, Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and Mu-class glutathione S-transferase genes. Jpn J Cancer Res 1992; 83:866-870. [PMID: 1399823]
17. Kao SY, Wu CH, Lin SC, Yap SK, Chang CS, Wong YK, Chi LY, Liu TY. Genetic polymorphism of cytochrome P4501A1 and susceptibility to oral squamous cell carcinoma and oral precancer lesions associated with smoking/betel use. J Oral Pathol Med 2002; 31:505-511. [PMID: 12269988]
18. Ketterer B, Harris JM, Talaska G, Meyer DJ, Pemble SE, Taylor JB, Lang NP, Kadlubar FF. The human glutathioneStransferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Environ Health Perspect 1992; 98:87-94. [PMID: 1486868]
19. Sundberg K, Seidel A, Mannervik B, Jernstrom B. Detoxification of carcinogenic fjord-region diol epoxides of polycyclic aromatic hydrocarbons by glutathione transferase P1-1 variants and glutathione. FEBS Lett 1998; 438:206-210. [PMID: 9827546]
20. Coles B, Ketterer B. The role of glutathione and glutathione transferases in chemical carcinogenesis. Crit Rev Biochem Mol Biol 1990; 25:47-70. [PMID: 2182291]
21. Seidegard J, Pero RW, Markowitz MM, Roush G, Miller DG, Beattie EJ. Isoenzyme(s) of glutathione transferase (class A) as a marker for the susceptibility to lung cancer: A follow up study. Carcinogenesis 1990; 11:33-36. [PMID: 2295125]
22. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, Ketterer B, Taylor JB. Human glutathione Stransferase (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994; 300:271-276. [PMID: 8198545]
23. McWilliams JE, Sanderson BJ, Harris EL, Richert-Boe KE, Henner WD. Glutathione S-transferase M1 (GSTM1) deficiency and lung cancer risk. Cancer Epidemiol Biomarkers Prev 1995; 4:589-94. [PMID: 8547824]
24. Sato M, Sato T, Izumo T, Amagasa T. Genetic polymorphism of drug-metabolizing enzymes and susceptibility to oral cancer. Carcinogenesis 1999; 20:1927-1931. [PMID: 10506106]
25. Katoh T, Kaneko S, Kohshi K, Munaka M, Kitagawa K, Kunugita N, Kunugita N, Ikemura K, Kawamoto T. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and oral cavity cancer. Int J Cancer 1999; 83:606-609. [PMID: 10521794]
26. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993; 85:1159-1164. [PMID: 8320745]
27. Cheng YW, Hsieh LL, Lin P, Chen CP, Chen CY, Lin TS, Su JM, Lee H. Gender difference in DNA adduct levels among non-smoking lung cancer patients. Environ Mol Mutagen 2001; 37:304-310. [PMID: 11424180]
28. Cheng YW, Hsieh LL, Lin P, Chen CP, Chen CY, Lin TS, Su JM, Lee H. Gender difference in DNA adduct levels among non-smoking lung cancer patients. Environ Mol Mutagen 2001; 37:304-310. [PMID: 11424180]
29. Tsai YY, Cheng YW, Lee H, Tsai FJ, Tseng SH, Chang KC. P53 gene mutation spectrum and the relationship between gene mutation and protein expression in pterygium. Mol Vis 2005; 11:50-55. [PMID: 15682042]
30. Gaillard C, Strauss F. Ethanol precipitation of DNA with linear polyacrylamide as carrier. Nucleic Acids Res 1990; 18:378.[PMID: 2326177]
31. Hayashi S, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P4501A1 gene. J Biochem 1991; 110:407-411. [PMID: 1722803]
32. Groppi A, Couttele C, Fleury B, Iron A, Beugeret J, Couzigous P. Glutathione S-transferase class mu in French alcoholic cirrhotic patients. Hum Genet 1991; 87:628-630. [PMID:1916767]
33. Lai TJ, Tsai YY, Cheng YW, Chiang CC, Lee H, Chou MC, Chang JH. An association between BPDE-like DNA adductslevels and P53 gene mutation in pterygium. Mol Vis 2006;12:1687-1691. [PMID: 17213797]
34. Lodovici M, Luceri C, Guglielmi F, Bacci C, Akpan V, Fonnesu ML, Boddi V, Dolara P. Benzo(a)pyrene diolepoxide (BPDE)-DNA adduct levels in leukocytes of smokers in relation to polymorphism of CYP1A1, GSTM1, GSTP1, GSTT1, and mEH. Cancer Epidemiol Biomarkers Prev 2004; 13:1342-1348. [PMID: 15298956]
35. Alexandrov K, Cascorbi I, Rojas M, Bouvier G, Kriek E, Bartsch H. CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation. Carcinogenesis 2002; 23:1969-1977. [PMID: 12507920]
36. Perera FP. Environment and cancer: who are susceptible? Science 1997; 278:1068-1073. [PMID: 9353182]
37. Kato S, Bowman ED, Harrington AM, Blomeke B, Shields PG. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J Natl Cancer Inst 1995; 87:902-907. [PMID: 7666479]
38. Rojas M, Alexandrov K, Cascorbi I, Brockmoller J, Likhachev A, Pozharisski K, Bouvier G, Auburtin G, Mayer L, Kopp-Schneider A, Roots I, Bartsch H. High benzo[a]pyrene diolepoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/MsPI-GSTM1*0/*0 genotypes. Pharmacogenetics 1998; 8:109-118. [PMID: 10022748]
39. Tang DL, Rundle A, Warburton D, Santella RM, Tsai WY, Chiamprasert S, Hsu YZ, Perera FP. Association between both genetic and environmental biomarkers and lung cancer:evidence of a greater risk of lung cancer in women smokers. Carcinogenesis 1998; 19:1949-1953. [PMID: 9855008]
40. Wei Q, Cheng L, Hong WK, Spitz MR. Reduced DNA repair capacity in lung cancer patients. Cancer Res 1996; 56:4103-4107. [PMID: 8797573]
41. Cheng L, Eicher SA, Guo Z, Hong WK, Spitz MR, Wei Q. Reduced DNA capacity in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev 1998; 7:465-468. [PMID:9641488]
42. Gao YT, Blor WJ, Zheng W, Ershow AG, Hsu CW, Levin LI, Zhang R. FraumeniJr JF. Lung cancer among Chinese women. Int J Cancer 1987; 40:604-609. [PMID: 2824385]
43. Hilgers JH. Pterygium: its incidence, heredity and etiology. Am J Ophthalmol 1960; 50:635-644. [PMID: 13714249]
44. Saw SM, Tan D. Pterygium: prevalence, demography and risk factors. Ophthalmic Epidemiol 1999; 6:219-228. [PMID:10487976]
45. Tsai YY, Bau DT, Chiang CC, Cheng YW, Tseng SH, Tsai FJ. Pterygium and genetic polymorphism of DNA double strandbreak repair gene Ku70. Mol Vis 2007; 13:1436-1440. [PMID: 17768380]
46. Tsai YY, Lee H, Tseng SH, Cheng YW, Tsai CH, Wu YH, Tsai FJ. Null type of glutathione S-transferase M1 polymorphismis associated with early onset pterygium. Mol Vis 2004; 10:458-461. [PMID: 15273656]
47. Kerb R, Brockmoller J, Reum T, Roots I. Deficiency of glutathione S-transferases T1 and M1 as heritable factors of increased cutaneous UV sensitivity. J Invest Dermatol 1997; 108:229-232. [PMID: 9008240]
48. Halliwell B, Gutteridge JMC. Antioxidant defences. In: Halliwell B, Gutteridge JMC, editors. Free Radicals in Biology and Medicine. 3rd ed. Oxford: Clarendon Press; 1999. p. 105-245.
49. Strange RC, Lear JT, Fryer AA. Polymorphism in glutathione Stransferase loci as a risk factor for common cancers. Arch Toxicol Suppl 1998; 20:419-428. [PMID: 9442313]
50. Ollier W, Davies E, Snowden N, Alldersea J, Fryer A, Jones P, Strange R. Association of homozygosity for glutathione-StransferaseGSTM1 null alleles with the Ro+/Laautoantibody profile in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39:1763-1764. [PMID:8843871]
51. Hainaut P, Vähäkangas K. p53 as a sensor of carcinogenic exposures: mechanisms of p53 protein induction and lessons from p53 gene mutations. Pathol Biol (Paris) 1997; 45:833-844. [PMID: 9769947]
52. Wei M, Wanibuchi H, Morimura K, Iwai S, Yoshida K, Endo G, Nakae D, Fukushima S. Carcinogenicity of dimethylarsinic acid in male F344 rats and genetic alterations in induced urinary bladder tumors. Carcinogenesis 2002; 23:1387-1397. [PMID: 12151359]
53. Hollstein M, Sidransky D, Vogelstein B. at al. p53 mutations in human cancers. Science 1991; 253:49-53. [PMID: 1905840]
54. Greenblatt MS, Bennett WP, Hollstein M. at al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855-4878. [PMID: 8069852]
55. Hussain SP, Harris CC. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 1998; 58:4023-4037. [PMID: 9751603]